Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1671–1676. doi: 10.1054/bjoc.2001.1843

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

S D Webley 1, R J Francis 1, R B Pedley 1, S K Sharma 1, R H J Begent 1, J A Hartley 1, D Hochhauser 1
PMCID: PMC2363686  PMID: 11401322

Abstract

An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials. It consists of a prodrug, 4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L -glutamic acid (ZD2767P) and a conjugate of the F(ab')2 anti-CEA antibody A5B7 and the bacterial enzyme carboxypeptidase G2 (CPG2). ZD2767P is converted by antibody-targeted CPG2 into an active bifunctional alkylating drug (ZD2767) at the tumour site. The IC 50 value of the prodrug against the human colorectal tumour LS174T cell line was 55 ± 9 μM following a 1 h exposure. In contrast, co-incubation of ZD2767P with CPG2 resulted in 229-fold increase in activity. Using a modified comet assay, DNA interstrand cross links (ISC) were detected within 1 h of ZD2767P + CPG2 treatment and were repaired by 24 h. A clear dose–response was seen between the level of ISC, growth inhibition and ZD2767 concentration. Administration of a therapeutic dose of ZD2767P 72 h after the F(ab′)2 A5B7 conjugate to mice bearing LS147T xenografts resulted in extensive ISC in the tumour after 1 h; repair was seen at 24 h. Tumour biopsies and peripheral lymphocytes were studied in 5 patients on the ADEPT phase I clinical trial. In 4 patients no ISC were detected. These patients also demonstrated poor localization of conjugate and no tumour response was seen. However a significant level of ISC was detected in one tumour biopsy, which also showed evidence of conjugate localization and clinical response. These studies demonstrate the application of the comet assay in the measurement of ISC in vitro and in clinical material and confirm that activation of ZD2767P results in the formation of DNA crosslinks. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: colorectal cancer, antibody, ADEPT, comet assay, interstrand crosslink

Full Text

The Full Text of this article is available as a PDF (65.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blakey D. C., Burke P. J., Davies D. H., Dowell R. I., East S. J., Eckersley K. P., Fitton J. E., McDaid J., Melton R. G., Niculescu-Duvaz I. A. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res. 1996 Jul 15;56(14):3287–3292. [PubMed] [Google Scholar]
  3. Blakey D. C., Valcaccia B. E., East S., Wright A. F., Boyle F. T., Springer C. J., Burke P. J., Melton R. G., Bagshawe K. D. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys. 1993 Jan-Jun;22(1-3):1–8. doi: 10.1007/BF03033863. [DOI] [PubMed] [Google Scholar]
  4. Eccles S. A., Court W. J., Box G. A., Dean C. J., Melton R. G., Springer C. J. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 1994 Oct 1;54(19):5171–5177. [PubMed] [Google Scholar]
  5. Fairbairn D. W., Olive P. L., O'Neill K. L. The comet assay: a comprehensive review. Mutat Res. 1995 Feb;339(1):37–59. doi: 10.1016/0165-1110(94)00013-3. [DOI] [PubMed] [Google Scholar]
  6. Hartley J. M., Spanswick V. J., Gander M., Giacomini G., Whelan J., Souhami R. L., Hartley J. A. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res. 1999 Mar;5(3):507–512. [PubMed] [Google Scholar]
  7. Melton R. G., Boyle J. M., Rogers G. T., Burke P., Bagshawe K. D., Sherwood R. F. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods. 1993 Jan 14;158(1):49–56. doi: 10.1016/0022-1759(93)90257-8. [DOI] [PubMed] [Google Scholar]
  8. Napier M. P., Sharma S. K., Springer C. J., Bagshawe K. D., Green A. J., Martin J., Stribbling S. M., Cushen N., O'Malley D., Begent R. H. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res. 2000 Mar;6(3):765–772. [PubMed] [Google Scholar]
  9. Sherwood R. F., Melton R. G., Alwan S. M., Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985 May 2;148(3):447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x. [DOI] [PubMed] [Google Scholar]
  10. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  11. Springer C. J., Antoniw P., Bagshawe K. D., Wilman D. E. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des. 1991 Nov;6(5):467–479. [PubMed] [Google Scholar]
  12. Springer C. J., Bagshawe K. D., Sharma S. K., Searle F., Boden J. A., Antoniw P., Burke P. J., Rogers G. T., Sherwood R. F., Melton R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer. 1991;27(11):1361–1366. doi: 10.1016/0277-5379(91)90010-b. [DOI] [PubMed] [Google Scholar]
  13. Springer C. J., Dowell R., Burke P. J., Hadley E., Davis D. H., Blakey D. C., Melton R. G., Niculescu-Duvaz I. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem. 1995 Dec 22;38(26):5051–5065. doi: 10.1021/jm00026a013. [DOI] [PubMed] [Google Scholar]
  14. Springer CJ, Niculescu-Duvaz I., I Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev. 1997 Jul 7;26(2-3):151–172. doi: 10.1016/s0169-409x(97)00032-x. [DOI] [PubMed] [Google Scholar]
  15. Sunters A., Springer C. J., Bagshawe K. D., Souhami R. L., Hartley J. A. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol. 1992 Jul 7;44(1):59–64. doi: 10.1016/0006-2952(92)90038-k. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES